Interferon Alpha Receptor I Antibodies And Their Use
AssigneeMedarex, Inc.
InventorsJosephine M. Cardarelli, Alison Witte, Mohan Srinivasan
Life of this patent
Estimating the term…
Abstract
The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
Claims23
A method of treating a type-I interferon-mediated disease or disorder in a subject in need of treatment comprising administering to the subject an isolated human monoclonal antibody, or an antigen-binding portion thereof, that specifically binds to human interferon alpha receptor 1 (IFNAR-I), wherein the antibody inhibits the biological activity of IFN-β and does not bind the same epitope as mouse monoclonal antibody 64G12 (ECACC Deposit No. 92022605), such that the type-I interferon mediated disease in the subject is treated.
A method of treating a type-I interferon-mediated disease or disorder in a subject in need of treatment comprising administering to the subject an effective amount of an isolated human monoclonal antibody, or an antigen-binding portion thereof, that cross-competes for binding to human interferon alpha receptor I (IFNAR-I) with a reference antibody, wherein the reference antibody is selected from the group consisting of:
- a) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 25;
- and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 29;
- b) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 26;
- and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 30;
- c) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 27;
- and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 31;
- and
- d) an antibody comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:
- 28;
- and a light chain variable region comprising the amino acid sequence of SEQ ID NO:
- 32.
Dependencies are inferred from the claim text.